Gain Therapeutics reports preclinical GT-02287 data showing disease-modifying potential in Parkinson's models

Gain Therapeutics, Inc.

GT-02287 rescued motor and cognitive deficits in GBA1 and idiopathic PD models; effects persisted >1 week after drug withdrawal.
GT-02287 improved mitochondrial function and reduced α-synuclein aggregation in GBA1-PD in vitro and in vivo models.
GT-02287 reduced Tau accumulation in GBA1-mutant and wild-type cell lines, suggesting potential for Alzheimer's disease.
Delayed GT-02287 administration restored motor function to control levels and reduced neurodegeneration markers (NfL).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.